The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases

Farmaco

Volumn 56, Issue 1-2, 2001, Pages 51-56

  Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

4 Anilinoquinazolines; Epidermal growth factor receptor; Irreversible inhibitor; Tyrosine kinase inhibitors

Indexed keywords

4 ANILINOQUINAZOLINE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CANERTINIB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

BINDING SITE; CANCER CELL; CELL DIVISION; CONFERENCE PAPER; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; COMPUTER SIMULATION; ENZYME INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035272930     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(01)01026-6     Document Type: Conference Paper

References (34)

1. Discovering novel chemotherapeutic drugs for the third millennium
2. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors
3. The epidermal growth factor receptor and its inhibition in cancer therapy
4. Role of HER2 gene overexpression in breast carcinoma
5. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis
6. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
7. The epidermal growth factor receptor family of tyrosine kinases and cancer: can an atypical exemplar be a sound therapeutic target?
8. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor
9. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase
10. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
11. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-(phenylmethyl)amino- and 4-phenylaminoquinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of epidermal growth factor receptor
12. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]-pyrido[4,3-d]pyrimidines; a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor
13. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]-pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor
14. Tyrosine kinase inhibitors. 8. An unusually steep structure activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor
15. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor
16. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]-pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor
17. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors
18. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD- (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
19. Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase
20. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding
21. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase
22. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases
23. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases
24. Specific irreversible inactivation of the erbB receptor family by a new class of antitumor agents
25. Tyrosine kinase inhibitors. 15. 4-Anilinoquinazolines and pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP site of the epidermal growth factor receptor
26. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
27. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor
28. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)
29. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer
30. ZD (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): pharmacokinetics in a phase I study of patients with advanced cancer
31. Continuous administration of ZD (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability
32. Potentiation of cytotoxic agents against human tumors in mice by ZD (Iressa), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR
33. Therapy of human carcinomas in athymic mice by inhibtion of EGF receptor-mediated signal transduction with CP-358774; dynamics of receptor inhibition and anti-tumor effects